Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies

Non-small cell lung cancer (NSCLC) represents a heterogeneous group of malignancies characterised by diverse histological and molecular features. Some NSCLCs, particularly adenocarcinomas, harbour genomic alterations in receptor tyrosine kinases or downstream RAS/RAF signalling pathways, which are targets of effective therapies. NSCLCs lacking actionable genomic alterations often benefit from immune checkpoint inhibitors, though only a minority of patients achieve long-term survival. These tumours often carry alterations in tumour suppressor genes like TP53, KEAP1, STK11, or NF1, for which pharmacological strategies are still under investigation. This review explores emerging therapeutic opportunities unveiled by multi-omics studies in NSCLCs without actionable genomic alterations. Proteogenomic approaches—integrating genomic, transcriptomic and proteomic data—enable a comprehensive understanding of NSCLC molecular landscapes and signalling network dysregulation, helping to identify distinct tumour subtypes and potential therapeutic targets. These tumours exhibit alterations in cell cycle regulation, DNA repair, immune signalling, epigenetic modulation and metabolic and redox pathways. Although therapies targeting tumour suppressor genes like p53 remain highly anticipated, extending our understanding of the broader molecular landscape in these tumours may reveal novel vulnerabilities and inform the development of novel drugs or combination strategies. This could further advance precision oncology for NSCLC.

• Publication year

  2025

• Venue

  British Journal of Cancer

• Publication date

  2025-08-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41416-025-03139-6PMID 40849356PMCID 12603130
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Network-based multi-omics integrative analysis methods in drug discovery: a systematic review

  2025cited by this paper
• Thirty years of NRF2: advances and therapeutic challenges

  2025cited by this paper
• A Roadmap to Precision Immunotherapy for Early-Stage Non-Small Cell Lung Cancer.

  2025cited by this paper
• Translating premalignant biology to accelerate non-small-cell lung cancer interception

  2025cited by this paper
• Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator

  2025cited by this paper
• A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

  2025cited by this paper
• Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment

  2025cited by this paper
• Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma

  2024cited by this paper
• NRF2 inhibitors: Recent progress, future design and therapeutic potential.

  2024cited by this paper
• Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets

  2024cited by this paper
• Chromatin remodellers as therapeutic targets

  2024cited by this paper
• LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors

  2024cited by this paper
• Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC.

  2024cited by this paper
• Single-cell and spatial transcriptomics analysis of non-small cell lung cancer

  2024cited by this paper
• MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors

  2024cited by this paper
• Knowledge-guided learning methods for integrative analysis of multi-omics data

  2024cited by this paper
• Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations.

  2024cited by this paper
• Patient-Specific, Mechanistic Models of Tumor Growth Incorporating Artificial Intelligence and Big Data.

  2024cited by this paper
• Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation

  2024cited by this paper
• Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy

  2024cited by this paper
• Proteogenomic analysis of air-pollution-associated lung cancer reveals prevention and therapeutic opportunities

  2024cited by this paper
• BZW2 promotes malignant progression in lung adenocarcinoma through enhancing the ubiquitination and degradation of GSK3β

  2024cited by this paper
• Translating p53-based therapies for cancer into the clinic

  2024influential reference
• Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities

  2024cited by this paper
• Lung cancer in patients who have never smoked — an emerging disease

  2024cited by this paper
• Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer

  2024cited by this paper
• Proteogenomic analysis reveals non-small cell lung cancer subtypes predicting chromosome instability, and tumor microenvironment

  2024cited by this paper
• BZW2 is a potential regulator of non-small cell lung cancer progression.

  2024cited by this paper
• SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.

  2024cited by this paper
• CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

  2024cited by this paper
• Single-cell sequencing to multi-omics: technologies and applications

  2024cited by this paper
• The technological landscape and applications of single-cell multi-omics

  2023cited by this paper
• Pharmacological reactivation of p53 in the era of precision anticancer medicine

  2023influential reference
• Glutaminase inhibition as potential cancer therapeutics: current status and future applications

  2023cited by this paper
• First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

  2023cited by this paper
• Designing clinical trials for patients who are not average

  2023cited by this paper
• BZW2 Modulates Lung Adenocarcinoma Progression through Glycolysis-Mediated IDH3G Lactylation Modification.

  2023cited by this paper
• Efficacy and safety of veliparib combined with traditional chemotherapy for treating patients with lung cancer: a comprehensive review and meta-analysis

  2023cited by this paper
• Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

  2023cited by this paper
• Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden and recurrent somatic MLH1 inactivation.

  2023cited by this paper
• NF1 alterations in cancers: therapeutic implications in precision medicine

  2023cited by this paper
• A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.

  2023cited by this paper
• Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.

  2023cited by this paper
• KEAP1/NFE2L2 pathway signature outperforms KEAP1/NFE2L2 mutation status and reveals alternative pathway-activating mutations in Non-Small Cell Lung Cancer.

  2023cited by this paper
• CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer.

  2023cited by this paper
• Durvalumab in Combination with Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.

  2023cited by this paper
• Genomic mapping of metastatic organotropism in lung adenocarcinoma.

  2023cited by this paper
• The evolution of lung cancer and impact of subclonal selection in TRACERx

  2023influential reference
• The evolution of non-small cell lung cancer metastases in TRACERx

  2023cited by this paper
• Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.

  2023cited by this paper
• ARE-PROTACs Enable Co-degradation of an Nrf2-MafG Heterodimer.

  2023cited by this paper
• Methods and applications for single-cell and spatial multi-omics

  2023cited by this paper
• Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody

  2023cited by this paper
• Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

  2023cited by this paper
• Rare molecular subtypes of lung cancer

  2023cited by this paper
• Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

  2023cited by this paper
• NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer.

  2023cited by this paper
• Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

  2023cited by this paper
• Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways

  2022cited by this paper
• Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

  2022cited by this paper
• Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228.

  2022cited by this paper
• Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors

  2022cited by this paper
• Mutations of MSH5 in nonobstructive azoospermia (NOA) and rescued via in vivo gene editing

  2022cited by this paper
• Machine learning for multi-omics data integration in cancer

  2022cited by this paper
• High-resolution profiling of lung adenocarcinoma identifies expression subtypes with specific biomarkers and clinically relevant vulnerabilities.

  2022cited by this paper
• TNF Receptor Associated Factor 2 (TRAF2) Signaling in Cancer

  2022cited by this paper
• Advances and Trends in Omics Technology Development

  2022cited by this paper
• An update of Nrf2 activators and inhibitors in cancer prevention/promotion

  2022cited by this paper
• PROTACs: past, present and future.

  2022cited by this paper
• Multi-omics data integration approaches for precision oncology.

  2022cited by this paper
• Cancer proteogenomics: current impact and future prospects

  2022cited by this paper
• Integrated single-cell RNA sequencing analysis reveals distinct cellular and transcriptional modules associated with survival in lung cancer

  2022cited by this paper
• Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway

  2022influential reference
• Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management

  2022cited by this paper
• Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study

  2021cited by this paper
• Anomalous collapses of Nares Strait ice arches leads to enhanced export of Arctic sea ice

  2021cited by this paper
• Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway

  2021cited by this paper
• Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.

  2021cited by this paper
• Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway

  2021cited by this paper
• The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment.

  2021cited by this paper
• An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma

  2021cited by this paper
• Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer

  2021cited by this paper
• Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

  2021cited by this paper
• A proteogenomic portrait of lung squamous cell carcinoma.

  2021influential reference
• Evaluation and comparison of multi-omics data integration methods for cancer subtyping

  2021cited by this paper
• Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

  2021cited by this paper
• KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy.

  2021cited by this paper
• JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

  2021cited by this paper
• The MYC oncogene — the grand orchestrator of cancer growth and immune evasion

  2021cited by this paper
• SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.

  2021cited by this paper
• Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer

  2021cited by this paper
• Protein co-expression network-based profiles revealed from laser-microdissected cancerous cells of lung squamous-cell carcinomas

  2021cited by this paper
• Diminished efficacy of PD-(L)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is impacted by KRAS mutation status.

  2021cited by this paper
• Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms

  2021cited by this paper
• Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019

  2021cited by this paper
• Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint.

  2020cited by this paper
• The National Lung Matrix Trial of personalized therapy in lung cancer

  2020cited by this paper
• Re-epithelialization and immune cell behaviour in an ex vivo human skin model

  2020cited by this paper
• Genomic landscape of lung adenocarcinoma in East Asians

  2020cited by this paper
• Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells

  2020cited by this paper

• MCOAN: multimodal contrastive representation learning for cross-omics adaptive disease regulatory network prediction

  2026cites this paper